Characterization of doravirine-selected resistance patterns from participants in treatment-naive Phase 3 clinical trials

被引：0
|
作者：
Lai, M. -T. [1 ]
Xu, M. [2 ]
Ngo, W. [3 ]
Feng, M. [3 ]
Hazuda, D. [3 ]
Hanna, G. [4 ]
Kumar, S. [5 ]
Xu, X. [6 ]
Martin, E. [4 ]
Hwang, C. [4 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] Merck & Co Inc, Dept Pharmacol, West Point, PA USA
[3] Merck & Co Inc, Dept Antiviral Res, West Point, PA USA
[4] Merck & Co Inc, Dept Clin Res, West Point, PA USA
[5] Merck & Co Inc, Dept Clin Sci & Study Management, West Point, PA USA
[6] Merck & Co Inc, Dept Biostat, West Point, PA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
THPDB0101
引用
收藏
页码：137 / 138
页数：2
相关论文
共 50 条
  • [1] Doravirine resistance profile in clinical isolates and impact of baseline NNRTI resistance-associated mutations observed in treatment-naive participants from phase 3 clinical trials
    Asante-Appiah, E.
    Lai, J.
    Li, Q.
    Yang, D.
    Martin, E. A.
    Sklar, P.
    Hazuda, D.
    Petropoulos, C. J.
    Walworth, C.
    Grobler, J. A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 119 - 120
  • [2] Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials
    Woyach, Jennifer A.
    BLOOD, 2019, 134 (21) : 1796 - 1801
  • [3] Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials
    Woyach, Jennifer A.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2019, : 476 - 481
  • [4] Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
    White, Kirsten L.
    Raffi, Francois
    Miller, Michael D.
    VIRUSES-BASEL, 2014, 6 (07): : 2858 - 2879
  • [5] Clinical virology findings from treatment-naive and treatment-experienced genotype 1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase 3 clinical trials
    Kieffer, T. L.
    De Meyer, S.
    Bartels, D. J.
    Sullivan, J. C.
    Dierynck, I.
    Adda, N.
    Kwong, A.
    Jacobson, I. M.
    Sherman, K. E.
    Zeuzem, S.
    Picchio, G.
    ANTIVIRAL THERAPY, 2011, 16 : A27 - A27
  • [6] Safety and efficacy of doravirine in treatment-naive adults with HIV-1: 4 years of experience from the DRIVE-FORWARD and DRIVE-AHEAD clinical trials
    Molina, J. M.
    Orkin, C.
    Cahn, P.
    Lombaard, J.
    Supparatpinyo, K.
    Campbell, H.
    Wan, H.
    Teal, V.
    Asante-Appiah, E.
    Sklar, P.
    Teppler, H.
    Lahoulou, R.
    HIV MEDICINE, 2021, 22 : 29 - 30
  • [7] Characterization of Emergent HIV Resistance in Treatment-Naive Subjects Enrolled in a Vicriviroc Phase 2 Trial
    McNicholas, Paul
    Wei, Yi
    Whitcomb, Jeannette
    Greaves, Wayne
    Black, Todd A.
    Tremblay, Cecile L.
    Strizki, Julie M.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (10): : 1470 - 1480
  • [8] Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies
    Steinman, Lawrence
    Fox, Edward
    Hartung, Hans-Peter
    Alvarez, Enrique
    Qian, Peiqing
    Wray, Sibyl
    Robertson, Derrick
    Huang, Deren
    Selmaj, Krzysztof
    Wynn, Daniel
    Bosco, Jenna
    Mok, Koby
    Garner, Christopher A.
    Cree, Bruce
    NEUROLOGY, 2023, 100 (17)
  • [9] Disease outcomes with ublituximab in treatment-naive participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis
    Steinman, L.
    Fox, E. J.
    Hartung, H. -P.
    Alvarez, E.
    Qian, P.
    Wray, S.
    Robertson, D.
    Huang, D.
    Selmaj, K.
    Wynn, D.
    Bosco, J. A.
    Mok, K.
    Garner, C. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 605 - 606
  • [10] Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials
    Spinelli, Frank
    Prakash, Manyu
    Slater, Jill
    van der Kolk, Mike
    Bassani, Niccolo
    Grove, Richard
    Wynne, Brian
    van Wyk, Jean
    Clark, Andrew
    HIV RESEARCH & CLINICAL PRACTICE, 2021, 22 (02) : 46 - 54
12345